A Spectacular Easter for Rite Aid, Hits New High - Analyst Blog

By
A A A

Drugstore chain retailer, Rite Aid Corporation ( RAD ) saw the highest improvement in its monthly comparable store sales (comps) in about a decade with comps for the four weeks ended Apr 26, 2014 increasing 5.0%. This marked a significant turnaround in the company's performance since the start of 2014.

Buoyed by the spectacular comps performance, shares of Rite Aid moved up 5.48% on the index during yesterday's trade. Shares of the nation's third largest drugstore chain, following Walgreen Co. ( WAG ) and CVS Caremark Corp. ( CVS ), touched a 52-week and multi-year high of $7.90 during the day's trade before closing at $7.70. This represented the stock's most spectacular run on the index since 2001, when the stock last hit the 52-week high mark. Moreover, the stock has been a star performer amassing a massive return of 197.3% in one year's time and about 52.8% year-to-date.

Rite Aid, which also competes with Herbalife Ltd. ( HLF ), attributed the growth in comps for April to a rise in front-end and pharmacy comps as well as an improvement in prescription count at comparable stores.


Front-end comps for the month reflected 4.7% growth that came primarily on the back of strong Easter-related sales during the month as Easter moved into April this year versus March last year. Of the total comps growth at front-end stores, the company accredited 4.6% to Easter related sales.

Pharmacy comps for April were up 5.2%, which included a negative impact of nearly 138 basis points from generic drug introduction. Moreover, the company witnessed a 2.3% increase in prescription count at comparable stores.

Rite Aid's total drugstore sales for the month stood at $1.995 billion, up 4.9% from the year-ago figure of $1.902 billion. Prescription sales constituted 67.9% of the total drugstore sales while third-party prescription sales accounted for 97.4% of pharmacy sales.

On a year-to-date basis (8-weeks ended Apr 26), Rite Aid's comps grew 2.9% primarily due to 4.3% rise in pharmacy comps, while front-end comps declined 0.2%. The company also gained from a 1.7% rise in prescription counts for the period.

Total drugstore sales for the period grew 2.6% to $3,941 billion against $3,841 billion in the year-ago comparable period. Prescription sales constituted 68.7% of total drugstore sales. Third-party prescription sales accounted for 97.4% of pharmacy sales.

Looking ahead, the company's sustained focus on expanding pharmacy and clinical services through its Wellness+ customer loyalty program and remodeling of wellness stores raise our hopes. We believe that such measures will enable the company to broaden its customer base and boost top- and bottom-line performance.

Rite Aid currently has a Zacks Rank #1 (Strong Buy).



CVS CAREMARK CP (CVS): Free Stock Analysis Report

HERBALIFE LTD (HLF): Free Stock Analysis Report

RITE AID CORP (RAD): Free Stock Analysis Report

WALGREEN CO (WAG): Free Stock Analysis Report

To read this article on Zacks.com click here.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: Investing , Business , Stocks

Referenced Stocks: CVS , HLF , RAD , WAG

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

3 Great Stay-at-Home Jobs
3 Great Stay-at-Home Jobs           

Stocks

Referenced

Most Active by Volume

118,939,167
  • $114.57 ▼ 3.27%
74,292,430
  • $40.32 ▲ 2.05%
69,444,394
  • $3.505 ▲ 4.94%
65,835,007
  • $17.795 ▲ 0.14%
35,064,345
  • $37.27 ▲ 12.43%
32,040,028
  • $21.755 ▲ 9.60%
31,088,441
  • $5.23 ▲ 1.55%
28,682,728
  • $121.31 ▲ 7.77%
As of 8/4/2015, 03:59 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com